UroGen Submits NDA for UGN-103 Bladder Cancer Treatment
Princeton, New Jersey — August 17, 2026 UroGen Pharma Ltd. announced the submission of a New Drug Application (NDA)...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Princeton, New Jersey — August 17, 2026 UroGen Pharma Ltd. announced the submission of a New Drug Application (NDA)...
PRINCETON, N.J., May 15, 2026 UroGen Pharma Ltd. announced positive six-month results from the ongoing Phase 3 UTOPIA trial,...
